MX2019006220A - Ligandos opioides kappa de heteroaril fenoxi benzamida. - Google Patents
Ligandos opioides kappa de heteroaril fenoxi benzamida.Info
- Publication number
- MX2019006220A MX2019006220A MX2019006220A MX2019006220A MX2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- heteroarylphenoxy
- benzamide
- kappa opioid
- opioid ligands
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000027626 Neurocognitive disease Diseases 0.000 abstract 1
- 208000013200 Stress disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona compuestos de la Formula I: (ver fórmula) y sales farmaceuticamente aceptables de los mismos, en donde las variables R1, R2, R3, R4, R9, X, m y n son como se definen en la presente; procesos para la preparacion de; intermediarios utilizados en la preparacion de; y composiciones que contienen tales compuestos o sales; y sus usos para tratar trastornos asociados con opioides kappa (?-opioide) incluyendo, por ejemplo, un trastorno neurologico, o trastorno psiquiatrico tal como un trastorno neurocognitico, trastorno de abuso de sustancias, trastorno depresivo, trastorno de ansiedad, trastorno relacionado con trauma o estres y trastorno alimenticio.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426980P | 2016-11-28 | 2016-11-28 | |
| US201762576435P | 2017-10-24 | 2017-10-24 | |
| US201762585016P | 2017-11-13 | 2017-11-13 | |
| PCT/IB2017/057418 WO2018096510A1 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019006220A true MX2019006220A (es) | 2019-10-07 |
| MX389806B MX389806B (es) | 2025-03-20 |
Family
ID=60782279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006220A MX389806B (es) | 2016-11-28 | 2017-11-27 | Ligandos opioides kappa de heteroaril fenoxi benzamida |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10316021B2 (es) |
| EP (1) | EP3544972B8 (es) |
| JP (1) | JP7051853B2 (es) |
| CN (1) | CN110234638B (es) |
| AU (1) | AU2017365123B2 (es) |
| DK (1) | DK3544972T3 (es) |
| ES (1) | ES2947293T3 (es) |
| FI (1) | FI3544972T3 (es) |
| HR (1) | HRP20230518T1 (es) |
| HU (1) | HUE061945T2 (es) |
| IL (1) | IL266962B (es) |
| MX (1) | MX389806B (es) |
| PH (1) | PH12019501172A1 (es) |
| PL (1) | PL3544972T3 (es) |
| PT (1) | PT3544972T (es) |
| RS (1) | RS64258B1 (es) |
| TW (1) | TWI720272B (es) |
| WO (1) | WO2018096510A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018223177B2 (en) * | 2017-02-24 | 2024-05-02 | Xeniopro GmbH | Aromatic compounds which enhance notch signaling, for use in therapy |
| WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| CA3140164A1 (en) * | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Compounds and methods for the treatment of covid-19 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| IL315415A (en) | 2022-03-07 | 2024-11-01 | Janssen Pharmaceuticals Inc | The compositions containing eticarpant |
| CA3254365A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION |
| CA3254503A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | PURE FORMS OF CRYSTALLINE ATICAPRANT |
| EP4602033A1 (en) * | 2022-10-12 | 2025-08-20 | Adama Makhteshim Ltd. | Process for the preparation of aminopyridazine derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2000159747A (ja) * | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| US6420415B1 (en) * | 1998-09-21 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Thiol compounds, their production and use |
| IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
| UA80437C2 (en) | 2002-09-19 | 2007-09-25 | Lilly Co Eli | Diaryl ethers as opioid receptor antagonist |
| US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| ATE406360T1 (de) | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| CN101120055B (zh) | 2005-02-18 | 2014-07-23 | 日本曹达株式会社 | 有机无机复合体 |
| WO2007105637A1 (ja) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| RS51211B (sr) | 2006-04-04 | 2010-12-31 | Emodis Gmbh. | Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja |
| NZ586225A (en) * | 2008-01-22 | 2012-05-25 | Lilly Co Eli | Kappa selective opioid receptor antagonist |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| CR11559A (es) | 2008-03-25 | 2010-10-20 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
| US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CA2746943A1 (en) | 2008-12-18 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Serotonin 5-ht2b receptor inhibitors |
| HN2010001319A (es) | 2009-01-26 | 2013-01-15 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
| WO2014053210A1 (en) | 2012-10-02 | 2014-04-10 | Merck Patent Gmbh | Pyrrolidines |
| WO2015109080A1 (en) | 2014-01-15 | 2015-07-23 | Research Triangle Institute | Kappa-opioid receptor selective opioid receptor antagonists |
| WO2016086149A1 (en) | 2014-11-26 | 2016-06-02 | University Of Kansas | Antagonists of the kappa opioid receptor |
-
2017
- 2017-11-22 US US15/820,679 patent/US10316021B2/en active Active
- 2017-11-27 EP EP17818281.2A patent/EP3544972B8/en active Active
- 2017-11-27 WO PCT/IB2017/057418 patent/WO2018096510A1/en not_active Ceased
- 2017-11-27 TW TW106141134A patent/TWI720272B/zh active
- 2017-11-27 FI FIEP17818281.2T patent/FI3544972T3/fi active
- 2017-11-27 PT PT178182812T patent/PT3544972T/pt unknown
- 2017-11-27 JP JP2019528746A patent/JP7051853B2/ja active Active
- 2017-11-27 CN CN201780084763.0A patent/CN110234638B/zh active Active
- 2017-11-27 MX MX2019006220A patent/MX389806B/es unknown
- 2017-11-27 AU AU2017365123A patent/AU2017365123B2/en active Active
- 2017-11-27 RS RS20230453A patent/RS64258B1/sr unknown
- 2017-11-27 HR HRP20230518TT patent/HRP20230518T1/hr unknown
- 2017-11-27 PL PL17818281.2T patent/PL3544972T3/pl unknown
- 2017-11-27 ES ES17818281T patent/ES2947293T3/es active Active
- 2017-11-27 DK DK17818281.2T patent/DK3544972T3/da active
- 2017-11-27 HU HUE17818281A patent/HUE061945T2/hu unknown
-
2019
- 2019-05-28 IL IL266962A patent/IL266962B/en unknown
- 2019-05-28 PH PH12019501172A patent/PH12019501172A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110234638A (zh) | 2019-09-13 |
| US10316021B2 (en) | 2019-06-11 |
| MX389806B (es) | 2025-03-20 |
| FI3544972T3 (fi) | 2023-06-02 |
| WO2018096510A1 (en) | 2018-05-31 |
| CN110234638B (zh) | 2022-10-21 |
| AU2017365123B2 (en) | 2022-02-17 |
| HRP20230518T1 (hr) | 2023-08-04 |
| TW201831460A (zh) | 2018-09-01 |
| HUE061945T2 (hu) | 2023-09-28 |
| RS64258B1 (sr) | 2023-07-31 |
| PT3544972T (pt) | 2023-06-20 |
| IL266962A (en) | 2019-07-31 |
| EP3544972B1 (en) | 2023-04-26 |
| EP3544972B8 (en) | 2023-06-07 |
| AU2017365123A1 (en) | 2019-07-11 |
| US20180148432A1 (en) | 2018-05-31 |
| IL266962B (en) | 2022-02-01 |
| JP7051853B2 (ja) | 2022-04-11 |
| TWI720272B (zh) | 2021-03-01 |
| PH12019501172A1 (en) | 2019-12-11 |
| EP3544972A1 (en) | 2019-10-02 |
| PL3544972T3 (pl) | 2023-07-24 |
| NZ754862A (en) | 2024-11-29 |
| ES2947293T3 (es) | 2023-08-04 |
| CA3045242A1 (en) | 2018-05-31 |
| DK3544972T3 (da) | 2023-05-30 |
| JP2019535799A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006220A (es) | Ligandos opioides kappa de heteroaril fenoxi benzamida. | |
| CL2018000024A1 (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl | |
| DOP2019000206A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| AR108012A1 (es) | Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl | |
| MX2020005348A (es) | Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida. | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| MX2019010539A (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak. | |
| MX2019000231A (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas. | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| CU20150118A7 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| MX2019012815A (es) | Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo. | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| CO2017005588A2 (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| CO2018003739A2 (es) | Sales de un inhibidor de pim quinasa | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| SV2016005306A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| MX2019007101A (es) | Derivados de oxazina como inhibidores de beta secretasa y metodos de uso. | |
| SV2016005305A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CR20150184A (es) | Derivados de n-(2-aminacíclica)etil)benzamida como inhibidores de p2x7 |